8-K: Nurix's Bexobrutideg Shows Superior Efficacy in CLL, WM

Nurix Therapeutics announced compelling new clinical data for its BTK degrader bexobrutideg in relapsed or refractory CLL, SLL, and WM, demonstrating durable responses and a favorable safety profile.

Summary

• Bexobrutideg (NX-5948) demonstrated an 83.0% objective response rate (ORR) and a median progression-free survival (PFS) of 22.1 months in heavily pretreated relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) patients in the Phase 1a study.
• The 600 mg dose of bexobrutideg, selected as the Recommended Phase 2 Dose (RP2D), showed an 83.3% ORR in the randomized Phase 1b cohort for CLL/SLL, outperforming the 200 mg dose (73.7% ORR).
• In patients with relapsed or refractory Waldenström Macroglobulinemia (WM), bexobrutideg achieved a 75.0% ORR, including 10.7% very good partial responses (VGPRs), with median duration of response (DOR) and PFS not yet reached after a median follow-up of 8.1 months.
• The drug was well tolerated across all studies, with a consistent safety profile and no dose-limiting toxicities or systemic fungal infections reported.
• Nurix has initiated the pivotal Phase 2 DAYBreak CLL-201 trial for accelerated approval in triple-exposed relapsed/refractory CLL and plans a confirmatory Phase 3 trial in H1 2026.

Sentiment

Score: 9

Explanation: The clinical data for bexobrutideg across CLL/SLL and WM are highly positive, demonstrating superior efficacy and durability compared to existing treatments, particularly pirtobrutinib, in challenging patient populations. The drug's favorable safety profile, brain penetrance, and activity against resistance mutations further enhance its potential. The company's strong financial position and clear pivotal development pathway add to the positive outlook.

Positives

• Bexobrutideg achieved an 83.0% ORR and 22.1 months median PFS in heavily pretreated CLL/SLL patients, including those with BTK inhibitor resistance mutations and high-risk molecular features.
• The 600 mg dose demonstrated superior ORR (83.3%) and a trend towards longer PFS compared to the 200 mg dose in the randomized Phase 1b CLL/SLL cohort, supporting its selection as the RP2D.
• In WM patients, bexobrutideg showed a 75.0% ORR, with durable and deepening responses observed regardless of prior therapy or baseline MYD88/CXCR4 mutations.
• The drug exhibited a well-tolerated safety profile across all indications, with predominantly low-grade adverse events and no dose-limiting toxicities or Grade 4 infections.
• Bexobrutideg demonstrated clinical activity in patients with Central Nervous System (CNS) involvement in both CLL/SLL and WM, indicating brain penetrance.
• The company's financial position is strong, with $663.8 million in pro forma cash/investments and an expected cash runway into 2028, bolstered by a $250 million follow-on offering and $47 million in non-dilutive capital from partnerships.

Negatives

• Two treatment-emergent adverse events led to drug discontinuation in the WM study, though no Grade 5 AEs were observed.

Risks

• Risks inherent in the drug development process, including the unexpected emergence of adverse events or other undesirable side effects during clinical development.
• Uncertainties related to the timing and results of clinical trials.
• Whether Nurix will be able to fund its research and development activities and achieve its research and development goals.
• The impact of economic and market conditions and global and regional events on Nurix's business, clinical trials, financial condition, liquidity, and results of operations.
• Whether Nurix will be able to protect intellectual property.

Future Outlook

Nurix plans to advance bexobrutideg through pivotal clinical development, including the ongoing Phase 2 DAYBreak CLL-201 trial for accelerated approval and a planned confirmatory Phase 3 trial in H1 2026. The company also intends to initiate a Phase 1b/2 combination study for bexobrutideg with venetoclax (with or without rituximab/obinutuzumab) in 2L+ and 1L+ CLL. Beyond bexobrutideg, Nurix is progressing other degrader programs, including NX-1607, a BRAF degrader, and partnered programs with Sanofi (STAT6 degrader) and Gilead (IRAK4 degrader), and is developing a new bexobrutideg formulation for inflammatory and autoimmune diseases.

Management Comments

• "The clinical activity and durability observed with bexobrutideg in this study are highly encouraging for patients with relapsed or refractory CLL/SLL, many of whom have limited treatment options." Zulfa Omer, M.D., Assistant Professor of Internal Medicine at the University of Cincinnati.
• "Advancing the 600 mg dose into our pivotal DAYBreak program reflects our conviction that this regimen offers patients the greatest opportunity for sustained clinical benefit, supported by a favorable safety profile." Paula O'Connor, M.D., Chief Medical Officer of Nurix.
• "These exciting, positive results reinforce the potential for bexobrutideg to be best-in-class and form a strong foundation to support our pivotal development program." Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Nurix.
• "We believe bexobrutideg is an innovative therapy with the potential to transform care in CLL, WM, and additional NHL indications, while supporting long-term value creation as its development expands into inflammatory and autoimmune settings." Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Nurix.

Industry Context

Bexobrutideg represents a novel approach in the BTK inhibitor landscape by functioning as a BTK degrader, which addresses the BTK scaffolding function differently from traditional BTK inhibitors. This mechanism allows it to be active against wildtype BTK and overcome treatment-emergent resistance mutations, including those that confer resistance to covalent and non-covalent BTK inhibitors. Its ability to cross the blood-brain barrier also positions it uniquely to treat CNS involvement in B-cell malignancies, an area of high unmet need. The strong clinical data, particularly in heavily pretreated populations with high-risk features, suggests bexobrutideg could become a best-in-class therapy, potentially expanding treatment options for patients who have exhausted other BTK inhibitor therapies.

Comparison to Industry Standards

• Bexobrutideg's maturing data from Phase 1a in CLL patients demonstrates an ORR of 83.0%, median DOR of 20.1 months, and median PFS of 22.1 months.
• This compares favorably to pirtobrutinib (from the BRUIN-321 study), which reported an ORR of 65% (69% by investigator), a DOR of 13.8 months (13.9 by investigator), and a median PFS of 14.0 months overall (11.4 months in patients with prior cBTKi & BCL-2i).
• Bexobrutideg's superior ORR, DOR, and PFS were observed despite treating a patient population with less favorable baseline characteristics, including more prior lines of therapy (median of 4 vs. 3), higher percentage of patients with 4+ lines of prior therapy (56.3% vs. 33%), prior exposure to non-covalent BTK inhibitors (27% vs. 0%), and more patients exposed to prior BCL-2 inhibitors (83.3% vs. 50%).

Stakeholder Impact

• **Shareholders**: Positive clinical data and a clear development pathway for a potential best-in-class drug, coupled with a strong financial position, are likely to increase investor confidence and potentially drive share price appreciation.
• **Patients**: Bexobrutideg offers a highly effective and well-tolerated treatment option for patients with relapsed or refractory CLL, SLL, and WM, especially those who have failed previous BTK inhibitors or have high-risk mutations, addressing a significant unmet medical need.
• **Healthcare Providers**: The drug's efficacy in challenging patient populations and its favorable safety profile could make it a preferred treatment choice, expanding the therapeutic arsenal for B-cell malignancies.
• **Competitors**: The superior efficacy data compared to existing BTK inhibitors like pirtobrutinib could put pressure on competitors and potentially shift market share upon approval.

Next Steps

• Continue enrollment in the pivotal single-arm Phase 2 DAYBreak CLL-201 clinical trial (NCT07221500) for accelerated approval in relapsed/refractory CLL (triple-exposed).
• Initiate a confirmatory Phase 3 trial (DAYBreak CLL-306) in H1 2026 for full approval in 2L+ CLL patients with prior covalent BTK inhibitor exposure.
• Initiate a Phase 1b/2 combination study to evaluate bexobrutideg with venetoclax (and potentially rituximab/obinutuzumab) in 2L+ and 1L+ CLL.
• Continue enrollment in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) for bexobrutideg in patients with relapsed or refractory B-cell malignancies.
• Advance other proprietary and partnered degrader programs, including NX-1607, BRAF degrader, and partnered STAT6 and IRAK4 degraders.
• Initiate healthy volunteer studies with a new bexobrutideg formulation for inflammatory and autoimmune indications.

Key Dates

Recommendation

The filing presents exceptionally strong clinical data for bexobrutideg, demonstrating superior efficacy (ORR, PFS, DOR) compared to a recently approved competitor (pirtobrutinib) in a more challenging, heavily pretreated patient population for CLL/SLL. The positive results in WM, including durable responses and activity in CNS involvement, further broaden the drug's potential. The favorable safety profile, coupled with the strategic selection of the 600 mg dose for pivotal trials and a clear regulatory pathway for accelerated approval, de-risks future development. Furthermore, Nurix's robust financial position, bolstered by recent capital raises and partnership revenue, provides a long cash runway. These factors collectively indicate a high probability of commercial success and significant value creation, making it a strong buy for seasoned investors.

Keywords

Bexobrutideg, NX-5948, Nurix Therapeutics, BTK degrader, CLL, SLL, Waldenström Macroglobulinemia, WM, Oncology, Hematology, Clinical trial, Phase 1, Phase 2, ASH, Targeted protein degradation, B-cell malignancies